OUR BOARD MEMBERS
Luc Maruenda is currently a voting member of the Board at Biomodex. Luc joined Idinvest Partners in 1999, and is Partner in charge of the structuring, development and commercialization of Idinvest’s private asset management products, whilst also maintaining a role as Venture Capital investor, notably with regard to the monitoring of his investments. As the head of the Private Client Solutions department, since 1999, Luc has developed Idinvest’s private asset management offer so as to provide adapted solutions to the demands and constraints of French (and European) private investors: firstly with FCPIs, then with the development of new products offering asset diversification solutions on the different investment strategies deployed by Idinvest. Prior to joining Idinvest, Luc took part in the launch of a private equity program in the United Arab Emirates, where he took joint responsibility for the venture capital investments of The National Investor in Abu Dhabi. Before that, Luc was investment director in the offset team at Giat Industries (Nexter Group) in Abu Dhabi. Prior to that, he was CFO of the start-up Webcorp in San Francisco and worked as audit manager at Cabinet Constantin in Paris and then in New York for three years. Luc trained as an expert-comptable (chartered accountant equivalent) and holds a Master’s degree in Business…
Valéry Huot is currently a voting member of the Board at Biomodex. Valéry is a Managing Partner of Innovation Capital since 2004, joined LBO France in 2016 when the two companies merged. He has been involved in many trade sales and IPOs (Novaled, Aldebaran Robotics, RSI Video Systems, eFront, Anevia, Doubletrade, Netcentrex…) and sits at the board of several ongoing investments (BIOMODEX, BioSerenity, H4D, OpenHealth and Wandercraft). He started his career in Australia in a joint research lab between Telstra and Sydney Uni, then worked at the French Defense Procurement Agency and later at the French Treasury in charge of SMEs financing and innovation politics. He then co-led in 2001 the fund of fund activity of CDC Enterprises. Valéry graduated from Stanford University and Ecole Polytechnique.
François Thomas is currently a voting Board member at Biomodex as well as former Chairman. Francois is specialized in biotechnology, business development, venture capital, medical oncology and drug development. He is the head of the Inserm Transfert Initiative portfolio, managed since September 2017 by Sofimac Innovation. Director of Therachon, then censor (2015-2018), Annapurna (2015-2016, until the merger with Avalanche listed on NASDAQ), Enyo (censor since 2015), Step Pharma, Eyevensys, AelisFarma, BIOMODEX, Sensorion (2015 -2019), Censor of Inotrem (2015-2019). François studied oncology in France and also holds a master’s degree in management from Massachusetts Institute of Technology (MIT) – Sloan School of Management.
Karl Schweitzer is currently the Chairman of the Board at Biomodex. Karl has over the past 28 years Karl held numerous senior leadership roles. He gained extensive international experience in corporate as well as mid-size and start-up medical device companies for which he has raised more than $50 million. Karl is founder of Transform Medical GmbH which provides advice to VCs and invests in med-tech start-ups. He is also co-founder and CEO of Neuromodtronic GmbH. Prior to his involvement in start-up companies Karl spent almost ten years at Medtronic where he was Vice President for several businesses in the cardiac and neuro field. As Vice President and International General Manager he oversaw the global international business of the corporation’s $2 billion neuromodulation division. Karl started his career in medical devices with Eli Lilly’s MDD division. He then became Vice President at Boston Scientific before joining Medtronic. Throughout his successful career Karl has launched several industry firsts, including the first ever trans-catheter heart valve. Karl holds a MSc in business informatics, a JD in law and a MBA from INSEAD.
Dr. Jean-Luc G. Boulnois has over 30 years of international leadership experience in the medical device industry. He is President and CEO of Quadrature, a Boston-based strategic advisory firm for MedTech companies. Dr. Boulnois served as Chairman and CEO of Microline Surgical, Inc. (reposable minimally invasive electro-surgical instruments used in various surgical specialties) and led the acquisition of Starion Instruments in 2009. He also served as Venture Partner at Dover Medical Ventures, a Boston-based venture fund in creation dedicated to financing early-stage medical device enterprises. Further positions included Executive Director of New Technology at Arrow International; co-developer, President and CEO of Sometec, an innovative international company in the non-invasive cardiovascular monitoring space; President and COO of Technomed International Inc., an international urology company specializing in non-invasive ultrasound and laser technologies. Currently serves as Director of FineHeart, BIOMODEX, and Nido Surgical, three Venture Capital financed companies; he is also a Trustee of the French Cultural Center, a Boston non-profit organization. Dr. Boulnois is co-author of 6 books and more than 35 peer-reviewed scientific articles in applied physics and biophysics.
Mr. Ferrari is a Co-Founder of De Novo Ventures which had $650 million under management and was one of the premier firms dedicated to Medical Devices and Biotechnology. Rich has raised over a billion dollars for companies he has directly influenced and participated in approximately a 1.8 billion dollars in acquisition events. Additionally, and most recently Rich served as the CEO and Chairman of PQ Bypass which culminated in a successful acquisition to Endologix for $350Mill. Rich has been a successful CEO of two publicly traded medical technology companies. Cardiovascular Imaging Systems, the first and leading developer of ultrasound imaging catheters which was eventually acquired for $125 million by Boston Scientific. Additionally, Rich was the co-founder of the MTG Group which developed Ensure femoral closure device which sold to J&J for $100 Mill returning 10x to investors and also IVS which developed the Star Close and sold to Abbott for $100Mill also returning 10x to investors. Rich is also the co-founder of Transaortic an integrated femoral sheath and embolic capture system for TAVR procedure which sold last year to Medtronic. Rich is also co-founder of Tenon Medical an orthopedic device for treating SI-Joint Pain currently trading on NASDAQ under TNON.
Sidarth Radjou currently holds an observer role with the Board and is the historical technical co-founder of BIOMODEX. Sidarth graduated from Ecole Centrale Supelec as biomechanical engineer. His early research work on medical imaging and advanced materials at Agoranov led him to develop the early patented technology empowering BIOMODEX organ twins biomechanical accuracy.